Form 4: Prime Medicine Director Wendy Chung Receives 55,000 Stock Option Grant

Prime Medicine, Inc. Director Wendy Chung was granted 55,000 stock options with an exercise price of $1.32, set to vest by June 2026 or the next annual meeting.

Summary

• Wendy Chung, a Director of Prime Medicine, Inc. (PRME), was granted 55,000 stock options.
• The transaction date for this grant was June 4, 2025.
• Each stock option has an exercise price of $1.32.
• The options are for 55,000 shares of Common Stock.
• The options will vest in full upon the earlier of June 4, 2026, or the date of the next annual meeting of stockholders, contingent on Ms. Chung's continuous service to the Issuer.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Ms. Chung beneficially owns 55,000 derivative securities (stock options) directly.
• An Exhibit 24, Limited Power of Attorney, was filed, authorizing specific individuals to execute and file SEC forms on behalf of Wendy Chung.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder value, reflecting standard compensation practices and indicating continued commitment from the director.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Prime Medicine, Inc.
• The options provide a future incentive for the director to remain engaged and contribute to the company's success due to the vesting schedule.

Negatives

• The options do not represent an immediate cash inflow for the director, as they require future exercise and potential sale of shares.
• The vesting schedule ties the director's compensation to continued service, which is a standard practice but also a condition.

Risks

• The value of the stock options is dependent on the future market price of Prime Medicine's common stock; if the stock price does not exceed the exercise price of $1.32, the options may expire worthless.
• Vesting of the options is subject to the Reporting Person's continuous service to the Issuer through the vesting date.

Future Outlook

The stock options are designed to incentivize the director's long-term commitment and performance, with full vesting expected by June 2026 or the next annual meeting, aligning future efforts with shareholder value creation.

Industry Context

The grant of stock options to a director is a common and standard practice in the biotechnology and pharmaceutical industries, where long-term incentives are crucial for retaining talent and aligning leadership interests with the company's strategic goals and shareholder returns.

Comparison to Industry Standards

• Stock option grants are a prevalent form of equity compensation for directors across publicly traded companies, particularly in growth-oriented sectors like biotechnology, serving to align director incentives with long-term shareholder value creation.
• The specific size of the grant (55,000 options) and the exercise price ($1.32) would typically be evaluated against peer companies' compensation structures and the company's stage of development, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with long-term shareholder value, potentially leading to more focused decision-making for company growth.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The granted stock options will vest in full upon the earlier of June 4, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Recommendation

Keywords

Prime Medicine, PRME, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing